In:
Current Pharmaceutical Design, Bentham Science Publishers Ltd., Vol. 26, No. 14 ( 2020-05-15), p. 1614-1621
Abstract:
Ghrelin (GHRL) is a polypeptide that can specifically bind to the growth hormone secretagogue
receptor (GHSR). The expression of GHSR is significantly different in normal and prostate cancer (PC) tissues in humans. It is important to find an effective diagnostic method for the diagnosis and prognosis of
invasive PC/neuroendocrine prostate cancer (NEPC). Methods: GHRL and GHSR mRNA levels were determined by a quantitative real-time polymerase chain reaction
in PC tissues. The expression of GHRL and GHSR proteins was assessed by Western blot assay and immunohistochemistry. A GHRL polypeptide probe was synthesized by standard solid-phase polypeptide synthesis, and
labeled with Alexa Fluor 660. Confocal microscopy was used to capture fluorescence images. Living imaging analysis showed tumor areas of different invasiveness in mice models. Results: GHRL and GHSR mRNA levels were determined by a quantitative real-time polymerase chain reaction
in PC tissues. The expression of GHRL and GHSR proteins was assessed by Western blot assay and immunohistochemistry. A GHRL polypeptide probe was synthesized by standard solid-phase polypeptide synthesis, and
labeled with Alexa Fluor 660. Confocal microscopy was used to capture fluorescence images. Living imaging analysis showed tumor areas of different invasiveness in mice models. Conclusion: GHSR and GHRL might be used in molecular imaging diagnosis for invasive PC/NEPC in the future.
Type of Medium:
Online Resource
ISSN:
1381-6128
DOI:
10.2174/1381612826666191227160001
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2020
SSG:
15,3
Permalink
